Co-founders Dr. Noel Moya and Danae Moya discuss Delphistem's approach to diabetes cell therapy, the challenges of clinical translation, and the importance of milestone-driven development.
Delphistem co-founders Dr. Noel Moya, Chief Science Officer, and Danae Moya, Chief Operating Officer, were featured on the Zero Friction Podcast, hosted by Terry Coutsolioutsos of RevRx.
In the episode, the founders discuss their journey from scientific research to biotechnology entrepreneurship, sharing insights into Delphistem's mission to develop a functional cure for insulin-dependent diabetes.
A New Approach to Diabetes Treatment
Delphistem is developing a patient-specific stem cell therapy designed to restore the body's natural ability to produce insulin.
The approach combines insulin-producing cells derived from a patient's own induced pluripotent stem cells (iPSCs) with Celleon™, a proprietary encapsulation device designed to protect transplanted cells from immune attack without requiring systemic immunosuppression.
With Type 1 diabetes as its initial therapeutic focus, Delphistem aims to address one of the major challenges in cell replacement therapy: maintaining functional insulin-producing cells while minimizing immune-related complications.
Bridging the Gap Between Research and Clinical Development
The conversation explores the challenges of translating promising laboratory discoveries into viable therapies.
The founders discuss Delphistem's progress in cell differentiation, functional testing, and preclinical mouse studies, as well as the next phase of development involving larger animal models.
They also reflect on the importance of building a capital-efficient biotechnology company, balancing scientific ambition with practical development milestones and long-term patient accessibility.
From Scientific Milestones to Patient Impact
The episode highlights the importance of a focused development strategy, in which each milestone builds the evidence needed to advance toward clinical testing.
Since the episode was recorded in May 2026, Delphistem has continued advancing its preclinical program and received a $305,000 Phase I SBIR grant from the National Institutes of Health (NIH).
The company is currently pursuing a $3 million financing round, with an initial $1 million tranche intended to support the initiation of its next phase of preclinical pig studies.
Watch the Conversation and Read the Article
The full conversation is available through the Zero Friction Podcast, alongside a companion article published by RevRx on October 31, 2026: Why Diabetes Cell Therapy Needs a Clear Next Milestone
Originally recorded and published May 12, 2026.

